Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Methocarbamol 1500 mg film-coated tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Methocarbamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for The name of your medicine is Methocarbamol 1500 mg film-coated tablets, referred to as Methocarbamol tablets throughout this leaflet. Methocarbamol tablets contain the active substance methocarbamol. Methocarbamol belongs to the group of medicinal products known as muscle relaxants. Methocarbamol is used for the symptomatic treatment of painful muscular tension, especially in the lower back (lumbago). Methocarbamol tablets are used in adults.
2.
What you need to know before you take it
e Methocarbamol tablets Do not take Methocarbamol tablets
- if you are allergic to methocarbamol or any of the other ingredients of this medicine (listed in section 6)
- in the event of comatose or pre-comatose states
- if you suffer from nervous system (CNS) disorders
- if you suffer from pathological muscle weakness (myasthenia gravis)
- if you suffer from epilepsy page 1 of 6
Package Leaflet: Methocarbamol 1500 mg film-coated tablets
Warnings and precautions Talk to your doctor or pharmacist before taking methocarbamol:
- if you suffer from impaired kidney function and/or impaired liver function
- if you are having any medical investigations or tests as methocarbamol could interfere with the results. Tell your doctor that you are taking methocarbamol before you have the test Children and adolescents This medicinal product is not intended for use in children and adolescents as safety and efficacy in these patient groups have not been established. Other medicines and Methocarbamol tablets Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. The concomitant administration of methocarbamol and centrally acting medicinal products such as barbiturates, opiate derivates and appetite suppressants may potentiate the effect of these medicines. Methocarbamol can potentiate the effect of anticholinergic medicines such as atropine and some psychotropic medicines. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore methocarbamol must not be taken by patients with pathological muscle weakness (myasthenia gravis), who are being treated with pyridostigmine. Methocarbamol tablets with alcohol Consumption of alcohol during methocarbamol treatment may potentiate the effect of the medicine. Do not drink alcohol while you are taking Methocarbamol tablets. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy There is no experience available concerning the use of methocarbamol during pregnancy. The potential risk to humans is not known. You should not take methocarbamol during pregnancy. Breast-feeding It is not known whether methocarbamol and/or its metabolites pass into human milk. As a precautionary measure, you should not take Methocarbamol tablets if you are breastfeeding. Fertility No data are available concerning the influence of methocarbamol on human fertility. page 2 of 6
Package Leaflet: Methocarbamol 1500 mg film-coated tablets
Driving and using machines Methocarbamol may affect your ability to drive and use machines. It may make you feel dizzy and drowsy. Before you consider driving a vehicle or operating machinery, you should consider your state of health and the possible side effects of methocarbamol. Therefore, you should not perform these activities until you have sufficient experience to know that you have no such side effects. Information about some of the ingredients of this medicine Methocarbamol tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
3.
How to take it
Methocarbamol tablets Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. Unless otherwise prescribed by the doctor, the recommended dose for adults is 1500 mg 3 times a day (corresponding to 1 tablet 3 times daily). At the beginning of treatment, the recommended dose is 1500 mg 4 times a day (corresponding to 1 tablet 4 times a day). In very serious cases, a dose up to 7500 mg methocarbamol can be taken each day.
Elderly Elderly patients may only need half the usual dose to give the same relief from the pain and muscle spasms.
Liver impairment You may need a longer interval between taking the tablets if you have liver disease. You should always follow your doctor's instructions carefully. Route of administration Methocarbamol tablets are for oral use. Take the tablets with sufficient water. The score line is only there to help you break the tablet if you have difficulty swallowing it whole. page 3 of 6
Package Leaflet: Methocarbamol 1500 mg film-coated tablets
The duration of treatment depends on the symptoms caused by muscle tension, but should not exceed 30 days. If you take more Methocarbamol tablets than you should If you have taken too many Methocarbamol tablets, call your doctor straight away. The doctor will decide about the necessary actions. If you forget to take Methocarbamol tablets If you forget to take a dose, take the next dose when it is due. Do not take a double dose to make up for a forgotten dose. If you stop taking Methocarbamol tablets Inform your doctor if you intend to discontinue treatment with Methocarbamol tablets. Discontinuation is not expected to lead to any special effect. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4.
Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Rare (may affect up to 1 in 1,000 people): Conjunctivitis, headache, dizziness, metallic taste, decreased blood pressure, nasal congestion, angioedema (acute-onset swelling of parts of the tissue and skin), rash, itching, nettle rash (urticaria), fever Very rare (may affect up to 1 in 10,000 people): Anaphylactic reactions (allergic hypersensitivity reactions), loss of appetite, restlessness, anxiety, confusion, fainting, involuntary eye movement, giddiness, trembling, seizures, impaired vision, slow heart beat, hot flushes, retching (nausea) and vomiting Not known (frequency cannot be estimated from the available data): Drowsiness, disturbance of coordination Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible
Possible side effects
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. page 4 of 6
Package Leaflet: Methocarbamol 1500 mg film-coated tablets
By reporting side effects you can help provide more information on the safety of this medicine.
5.
How to store it
Methocarbamol tablets Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the blister after "EXP". The expiry date refers to the last day of that month. For PVC/aluminium blister packs Do not store above 30oC. For ACLAR/aluminium blister packs: No special storage conditions are required for this medicinal product. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
Contents of the pack and other information
What Methocarbamol tablets contain
- The active substance is methocarbamol. Each film-coated tablet contains 1500 mg methocarbamol.
- The other ingredients are: Tablet core: lactose monohydrate, croscarmellose sodium, sodium laurilsulfate, povidone, anhydrous colloidal silica, magnesium stearate. Film-coating: poly(vinylalcohol), titanium dioxide (E171), talc, macrogol 3350 What Methocarbamol tablets look like and contents of the pack Methocarbamol 1500 mg film-coated tablets are white, oblong, biconvex, film-coated tablets, 23 mm x 10 mm, with a score line on one side. The score line is only there to help you break the tablet if you have difficulty swallowing it whole. Methocarbamol 1500 mg film-coated tablets are available in packs containing 50 or 100 or 100 (2 packs of 50) film-coated tablets. Not all pack sizes may be marketed. The tablets in this pack are enclosed in PVC/aluminium blister strips. The tablets in this pack are enclosed in ACLAR/aluminium blister strips. Marketing Authorisation Holder Neuraxpharm UK Limited, page 5 of 6
Package Leaflet: Methocarbamol 1500 mg film-coated tablets
First Floor, Building 1410, Arlington Business Park, Theale, Reading, Berkshire RG7 4SA United Kingdom Manufacturer Neuraxpharm Pharmaceuticals, S.L. Avda. Barcelona, 69 08970 Sant Joan Despí Barcelona – Spain neuraxpharm Arzneimittel GmbH Elisabeth-Selbert-Str. 23 40764 Langenfeld Germany This leaflet was last revised in December 2025
page 6 of 6
Frequently asked questions about Methocarbamol 1500 mg film-coated tablets
How do I take Methocarbamol 1500 mg film-coated tablets?
Methocarbamol 1500 mg film-coated tablets comes as tablet containing 1500mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Methocarbamol 1500 mg film-coated tablets?
The active substance in Methocarbamol 1500 mg film-coated tablets is methocarbamol.
Are there equivalent medicines to Methocarbamol 1500 mg film-coated tablets?
Medicines with the same active substance, strength and form include: Methocarbamol 1500 mg film coated-Tablet, Methocarbamol 1500 mg tablets. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Methocarbamol 1500 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Methocarbamol 1500 mg film-coated tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: methocarbamol
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Symptomatic treatment of painful muscular tension, especially in the lower back (lumbago).
Methocarbamol is indicated in adults.
4.2. Posology and method of administration
Posology
Adults
The recommended dose for adults is 1500 mg methocarbamol 3 times a day.
At the beginning of the treatment a dose of 1500 mg methocarbamol 4 times a day is recommended.
In severe cases up to 7500 mg methocarbamol can be taken each day.
The duration of treatment depends on the symptoms of muscle tension but should not exceed 30 days.
Paediatric population
The safety and efficacy of Methocarbamol in children and adolescents have not been established.
Elderly patients
Half the maximum dose or less may be sufficient to produce a therapeutic response.
Patients with hepatic impairment
In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.
Method of administration
Methocarbamol is for oral use.
The film-coated tablets should be taken with sufficient water.
4.3. Contraindications
- Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1.
- Comatose or pre-comatose states
- Disorders of the central nervous system (CNS)
- Myasthenia gravis
- Epilepsy
4.4. Special warnings and precautions for use
Methocarbamol should be used with caution in patients with impaired renal and/or hepatic function.
Methocarbamol tablets contain lactose
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Methocarbamol tablets contain sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Interference with laboratory tests
Methocarbamol may cause colour interference in screening tests for hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
4.5. Interaction with other medicinal products and other forms of interaction
The concomitant administration of methocarbamol and centrally acting medicinal products such as barbiturates, opioids and appetite suppressants may potentiate the effect of these products.
Using methocarbamol together with alcohol may potentiate the effect of the medicinal product.
The effect of anticholinergics, such as atropine and other psychotropic medicinal products, may be increased by methocarbamol.
Consumption of alcohol during methocarbamol treatment may lead to an increased effect.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol must not be taken by patients with myasthenia gravis, especially those who are being treated with pyridostigmine.
4.6. Fertility, pregnancy and lactation
Pregnancy
There is no experience in the use of methocarbamol during pregnancy. Data from animal studies concerning effects on pregnancy, embryonic/foetal development, parturition and post- natal development are not available (see section 5.3). The potential risk to humans is not known. Methocarbamol should therefore not be used during pregnancy.
Breast-feeding
It is not known whether methocarbamol and/or its metabolites pass into human breast milk. Methocarbamol and/or its metabolites are excreted into the milk of lactating dogs. Therefore, methocarbamol should not be used during breast-feeding.
Fertility
No data are available concerning methocarbamol on human fertility.
4.7. Effects on ability to drive and use machines
Methocarbamol has moderate influence on the ability to drive and use machines as it may cause dizziness or drowsiness – especially if other medicinal products capable of causing drowsiness are also being taken.
Patients should be instructed that if dizziness or drowsiness occurs, these activities should be avoided.
4.8. Undesirable effects
The following undesirable effects were reported in connection with the use of methocarbamol.
Frequency data for adverse reactions are based on the following categories (where it has been possible to obtain frequency data from the literature):
Very common
Common
Uncommon
Rare
Very rare
Not known
≥ 1/10
≥ 1/100 to < 1/10
≥ 1/1,000 to < 1/100
≥ 1/10,000 to < 1/1,000
< 1/10,000
the frequency cannot be estimated from the available data
The following adverse reactions have been reported with the use of methocarbamol:
System organ class
Frequency according to MedDRA convention
Rare
Very rare
Not known
Infections and infestations
Conjunctivitis
Immune system disorders
Anaphylactic reaction
Metabolism and nutrition disorders
Decreased appetite
Psychiatric disorders
Restlessness, anxiety, confusional state
Nervous system disorders
Headache, dizziness, metallic taste
Syncope, nystagmus, giddiness, tremor, seizure
Somnolence, coordination disturbance
Eye disorders
Visual impairment, diplopia
Cardiac disorders
Bradycardia
Vascular disorders
Hypotension
Hot flush
Respiratory, thoracic and mediastinal disorders
Nasal congestion
Gastrointestinal disorders
nausea, vomiting
Skin and subcutaneous tissue disorders
Angioedema, rash, pruritus, urticaria
General disorders and administration site conditions
Pyrexia
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures and coma.
After oral intake of 22.5 to 50 g methocarbamol with suicidal intent, two patients experienced drowsiness, but recovered completely within 24 hours.
In the literature, 3 fatal cases have been reported after methocarbamol was ingested with large quantities of alcohol (2 cases) or opiates (1 case) with suicidal intent.
Management of overdose includes gastric lavage symptomatic therapy and monitoring of vital functions. The usefulness of haemodialysis in managing overdose has not been established.
💬 Ask about this leaflet
Ask anything about Methocarbamol 1500 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
Medicines containing Methocarbamol
- Methocarbamol 1500 mg film coated-Tablet
- Methocarbamol 1500 mg tablets
- Methocarbamol 750 mg film coated-Tablet
- Methocarbamol 750 mg film-coated tablets
- Methocarbamol 750 mg tablets
- Methocarbamol Aristo 750 mg Tablets
- Methocarbamol neuraxpharm 750 mg film-coated tablets
- Robaxin-750, 750 mg Film-coated Tablets